Real-world Study for the Safety of Albumin-Bound Paclitaxel in Malignant Tumors

CompletedOBSERVATIONAL
Enrollment

1,000

Participants

Timeline

Start Date

May 12, 2020

Primary Completion Date

February 1, 2024

Study Completion Date

February 1, 2024

Conditions
Cancer
Interventions
OTHER

Observational study

Observational study of this study, no interventions involved

Trial Locations (14)

Unknown

Anhui Cancer Hospital, Hefei

Maanshan People's Hospital, Maanshan

Hainan General Hospital, Haikou

The Fourth Hospital of Hebei Medical University, Shijiazhuang

Tumor Hospital of Harbin Medical University, Harbin

Henan Cancer Hospital, Zhengzhou

Inner Mongolia Autonomous Region Cancer Hospital, Hohhot

Liaoning Cancer Hospital, Shenyang

Zhongshan Hospital, Shanghai

Shanxi Provincial Cancer Hospital, Taiyuan

The First Affiliated Hospital of Xi'an Jiaotong University, Xi’an

The Second Affiliated Hospital of Xi'an Jiaotong University (Xibei Hospital), Xi’an

The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou

Cancer Hospital Chinese Academy of Medical Sciences, Beijing

All Listed Sponsors
lead

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

INDUSTRY

NCT04060290 - Real-world Study for the Safety of Albumin-Bound Paclitaxel in Malignant Tumors | Biotech Hunter | Biotech Hunter